Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11517006 | 0.86 | S1PR4 (0.45) | S1PR4NR4A2HTR3AKDM4EMEN1 | |
| SCHEMBL3748357 | 0.80 | CCR1 (0.48) | S1PR4NR4A2HTR3EHTR3BHTR3A | |
| SCHEMBL7939210 | 0.80 | NR4A2 (0.46) | NR4A2HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27787626 | 0.80 | S1PR4 (0.40) | S1PR4MEN1KMT2ACYSLTR2CYSLTR1 | |
| SCHEMBL27163083 | 0.77 | PIK3CG (0.42) | S1PR4NR4A2HTR3EHTR3BHTR3A | |
| SCHEMBL14251381 | 0.76 | BACE1 (0.52) | S1PR4KDM4EMEN1KMT2ADYRK1A | |
| SCHEMBL28815861 | 0.76 | S1PR4 (0.40) | S1PR4NR4A2KDM4EMEN1KMT2A | |
| SCHEMBL4049786 | 0.74 | S1PR4 (0.36) | S1PR4KDM4EKMT2ALMNAMAPT | |
| SCHEMBL13513030 | 0.73 | CYSLTR1 (0.59) | KDM4EMEN1KMT2ACYSLTR2CYSLTR1 | |
| SCHEMBL6750524 | 0.73 | KDM4E (0.67) | KDM4EMEN1KMT2ACYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101591291-A | The synthetic method of 2-ethenyl quinoline compound | INST MATERIA MEDICA CAMS (CN) | 2009-12-02 | — | — | CN | claimed |
| EP-2094664-A2 | A NEW PROCESS FOR THE PREPARATION OF MONTELUKAST | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2009-09-02 | — | — | EP | claimed |
| WO-2009053424-A9 | CRYSTALLINE SALT OF MONTELUKAST | INKE SA (ES) | 2009-08-06 | — | — | WO | claimed |
| US-20090111849-A1 | CRYSTALLINE SALT OF MONTELUKAST | INKE, SA (ES) | 2009-04-30 | — | — | US | claimed |
| WO-2009053424-A1 | CRYSTALLINE SALT OF MONTELUKAST | INKE, S.A. (ES) | 2009-04-30 | — | — | WO | claimed |
| EP-2053043-A1 | Crystalline salt of montelukast | INKE, S.A. (ES) | 2009-04-29 | — | — | EP | claimed |
| WO-2008098965-A1 | PROCESS FOR OBTAINING MONTELUKAST | INKE, S.A. (ES) | 2008-08-21 | — | — | WO | claimed |
| EP-1958936-A1 | Process for obtaining montelukast | INKE, S.A. (ES) | 2008-08-20 | — | — | EP | claimed |
| US-20080194825-A1 | PROCESS FOR OBTAINING MONTELUKAST | INKE, S.A. (ES) | 2008-08-14 | — | — | US | claimed |
| WO-2008049922-A2 | A NEW PROCESS FOR THE PREPARATION OF MONTELUKAST | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2008-05-02 | — | — | WO | claimed |
| CN-114907514-A | Multifunctional fiber and preparation method and application thereof | 北京洁尔爽高科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-106928136-B | A kind of method of graphene palladium cobalt sequential catalyst synthesis montestron sodium intermediate | 济南大学 | 2019-05-10 | — | — | CN | disclosed |
| CN-106928136-A | A kind of Graphene palladium cobalt sequential catalyst synthesizes the method for MK intermediate | 济南大学 | 2017-07-07 | — | — | CN | disclosed |
| CN-106928137-A | A kind of method of Graphene palladium copper catalysis synthesis MK chirality alcohol intermediate | 济南大学 | 2017-07-07 | — | — | CN | disclosed |
| CN-104109122-B | For synthesizing midbody compound of montelukast and preparation method thereof | 浙江奥翔药业股份有限公司 | 2017-03-29 | — | — | CN | disclosed |
| EP-1408033-A1 | DIBENZOCYCLOHEPTENE COMPOUND | Ube Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-6509476-B1 | Leukotriene antagonists; antiallergens, antiinflammatory agents, and antiasthmatic agents | THE UNIVERSITY OF EAST ANGLIA (GB) | 2003-01-21 | — | — | US | disclosed |
| US-6160120-A | Process for preparing n-benzyl indoles | ELI LILLY AND COMPANY (US) | 2000-12-12 | — | — | US | disclosed |
| US-5807866-A | Process for preparing N-benzyl indoles | THE UNIVERSITY OF EAST ANGLIA (GB) | 1998-09-15 | — | — | US | disclosed |
| EP-0775694-A2 | Process for preparing N-benzyl indoles | University of East Anglia (GB) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111849-A1 | CRYSTALLINE SALT OF MONTELUKAST | CMA1, CYSLTR1, SYMPK | S1PR4 714/4885NR4A2 2871/4885HTR3E 3445/4885 |
| US-20080194825-A1 | PROCESS FOR OBTAINING MONTELUKAST | CYSLTR1, CMA1, CYSLTR2 | S1PR4 1246/4885NR4A2 2996/4885HTR3E 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.